{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:34:07Z","timestamp":1786368847909,"version":"build-2736575974"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-026-04741-1","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:03:52Z","timestamp":1786367032000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["\u201cAcute-phase reactions to zoledronate in clinical practice: a prospective single center study of 1,150 patients.\u201d"],"prefix":"10.1007","volume":"91","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-3923-4907","authenticated-orcid":false,"given":"Vanesa","family":"Longobardi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Victoria","family":"Olmedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Fernanda","family":"Carballo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcela","family":"Esparza Ram\u00edrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesly","family":"Bazoalto Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Pineda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rub\u00e9n","family":"Abdala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Jerkovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Bel\u00e9n","family":"Zanchetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,10]]},"reference":[{"issue":"9","key":"4741_CR1","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1056\/NEJMoa011807","volume":"346","author":"IR Reid","year":"2002","unstructured":"I.R. Reid, J.P. Brown, P. Burckhardt, Z. Horowitz, P. Richardson, U. Trechsel, A. Widmer, J.P. Devogelaer, J.M. Kaufman, P. Jaeger, J.J. Body, M.L. Brandi, J. Broell, D.R. Micco, A.R. Genazzani, D. Felsenberg, J. Happ, M.J. Hooper, J. Ittner, G. Leb, H. Mallmin, T. Murray, S. Ortolani, A. Rubinacci, M. Saaf, G. Samsioe, L. Verbruggen, P.J. Meunier, Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl. J. Med. 346(9), 653\u2013661 (2002). . https:\/\/doi.org\/10.1056\/NEJMoa011807","journal-title":"N Engl. J. Med."},{"issue":"18","key":"4741_CR2","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"DM Black","year":"2007","unstructured":"D.M. Black, P.D. Delmas, R. Eastell, I.R. Reid, S. Boonen, J.A. Cauley, F. Cosman, P. Lakatos, P.C. Leung, Z. Man, C. Mautalen, P. Mesenbrink, H. Hu, J. Caminis, K. Tong, T. Rosario-Jansen, J. Krasnow, T.F. Hue, D. Sellmeyer, E.F. Eriksen, S.R. Cummings, HORIZON Pivotal Fracture Trial, Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl. J. Med. 356(18), 1809\u20131822 (2007). . https:\/\/doi.org\/10.1056\/NEJMoa067312","journal-title":"N Engl. J. Med."},{"issue":"9","key":"4741_CR3","doi-asserted-by":"publisher","first-page":"4380","DOI":"10.1210\/jc.2010-0597","volume":"95","author":"IR Reid","year":"2010","unstructured":"I.R. Reid, G.D. Gamble, P. Mesenbrink, P. Lakatos, D.M. Black, Characterization of and risk factors for the acute-phase response after zoledronic acid. J. Clin. Endocrinol. Metab. 95(9), 4380\u20134387 (2010).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"4741_CR4","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1002\/jbmr.1797","volume":"28","author":"JL Welton","year":"2013","unstructured":"J.L. Welton, M.P. Morgan, S. Mart\u00ed, M.D. Stone, B. Moser, A.K. Sewell, J. Turton, M. Eberl, Monocytes and \u03b3\u03b4 T cells control the acute-phase response to intravenous zoledronate: insights from a phase IV safety trial. J. Bone Min. Res. 28(3), 464\u2013471 (2013). . https:\/\/doi.org\/10.1002\/jbmr.1797","journal-title":"J. Bone Min. Res."},{"issue":"8","key":"4741_CR5","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1007\/s00198-010-1448-2","volume":"22","author":"SL Silverman","year":"2011","unstructured":"S.L. Silverman, A. Kriegman, J. Goncalves, F. Kianifard, T. Carlson, E. Leary, Effect of acetaminophen and fluvastatin on post-dose symptoms following infusion of zoledronic acid. Osteoporos. Int. 22(8), 2337\u20132345 (2011). https:\/\/doi.org\/10.1007\/s00198-010-1448-2","journal-title":"Osteoporos. Int."},{"issue":"2","key":"4741_CR6","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s00198-011-1563-8","volume":"23","author":"JD Wark","year":"2012","unstructured":"J.D. Wark, W. Bensen, C. Recknor, O. Ryabitseva, J. 3rd Chiodo, P. Mesenbrink, de T.J. Villiers, Treatment with acetaminophen\/paracetamol or ibuprofen alleviates post-dose symptoms related to intravenous infusion with zoledronic acid 5\u00a0mg. Osteoporos. Int. 23(2), 503\u2013512 (2012). https:\/\/doi.org\/10.1007\/s00198-011-1563-8","journal-title":"Osteoporos. Int."},{"key":"4741_CR7","doi-asserted-by":"publisher","first-page":"106002802513675","DOI":"10.1177\/10600280251367582","volume":"16","author":"Q Wang","year":"2025","unstructured":"Q. Wang, W. Zhang, W. Lu, W. Ai, The Effect of Prophylactic Use of NSAIDs on Acute Phase Reactions Induced by First-Time Zoledronic Acid Treatment for Osteoporosis. Ann. Pharmacother. 16, 10600280251367582 (2025). https:\/\/doi.org\/10.1177\/10600280251367582","journal-title":"Ann. Pharmacother"},{"issue":"5","key":"4741_CR8","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1002\/jbmr.4802","volume":"38","author":"R Murdoch","year":"2023","unstructured":"R. Murdoch, A. Mellar, A.M. Horne, E. Billington, P.L. Chan, G.D. Gamble, I.R. Reid, Effect of a Three-Day Course of Dexamethasone on Acute Phase Response Following Treatment With Zoledronate: A Randomized Controlled Trial. J. Bone Min. Res. 38(5), 631\u2013638 (2023)","journal-title":"J. Bone Min. Res."},{"issue":"3","key":"4741_CR9","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1359\/jbmr.090819","volume":"25","author":"F Bertoldo","year":"2010","unstructured":"F. Bertoldo, S. Pancheri, S. Zenari, S. Boldini, B. Giovanazzi, M. Zanatta, M.T. Valenti, L. Dalle Carbonare, V. Lo Cascio, Serum 25-hydroxyvitamin D levels modulate the acute-phase response associated with the first nitrogen-containing bisphosphonate infusion. J. Bone Min. Res. 25(3), 447\u2013454 (2010). . https:\/\/doi.org\/10.1359\/jbmr.090819","journal-title":"J. Bone Min. Res."},{"issue":"5","key":"4741_CR10","doi-asserted-by":"publisher","first-page":"405","DOI":"10.4158\/EP161638.OR","volume":"24","author":"C Crotti","year":"2018","unstructured":"C. Crotti, N.B. Watts, De M. Santis, A. Ceribelli, G. Fabbriciani, F. Cavaciocchi, B. Marasini, C. Selmi, M. Massarotti, Acute Phase Reactions After Zoledronic Acid Infusion: Protective Role Of 25-Hydroxyvitamin D And Previous Oral Bisphosphonate Therapy. Endocr. Pract. 24(5), 405\u2013410 (2018).","journal-title":"Endocr. Pract."},{"issue":"5","key":"4741_CR11","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1007\/s00223-011-9468-2","volume":"88","author":"P Makras","year":"2011","unstructured":"P. Makras, A.D. Anastasilakis, S.A. Polyzos, I. Bisbinas, G.T. Sakellariou, S.E. Papapoulos, No effect of rosuvastatin in the zoledronate-induced acute-phase response. Calcif Tissue Int. 88(5), 402\u2013408 (2011). https:\/\/doi.org\/10.1007\/s00223-011-9468-2","journal-title":"Calcif Tissue Int."},{"issue":"1","key":"4741_CR12","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.bone.2010.10.177","volume":"49","author":"K Thompson","year":"2011","unstructured":"K. Thompson, F. Keech, D.J. McLernon, K. Vinod, R.J. May, W.G. Simpson, M.J. Rogers, D.M. Reid, Fluvastatin does not prevent the acute-phase response to intravenous zoledronic acid in post-menopausal women. Bone. 49(1), 140\u2013145 (2011).","journal-title":"Bone"},{"issue":"1","key":"4741_CR13","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/jbmr.521","volume":"27","author":"M Rossini","year":"2012","unstructured":"M. Rossini, S. Adami, O. Viapiana, R. Ortolani, A. Vella, E. Fracassi, D. Gatti, Circulating \u03b3\u03b4 T cells and the risk of acute-phase response after zoledronic acid administration. J. Bone Min. Res. 27(1), 227\u2013230 (2012). . https:\/\/doi.org\/10.1002\/jbmr.521","journal-title":"J. Bone Min. Res."},{"issue":"6","key":"4741_CR14","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1007\/s00198-017-3992-5","volume":"28","author":"AW Popp","year":"2017","unstructured":"A.W. Popp, R. Senn, I. Curkovic, C. Senn, H. Buffat, P.F. Popp, K. Lippuner, Factors associated with acute-phase response of bisphosphonate-na\u00efve or pretreated women with osteoporosis receiving an intravenous first dose of zoledronate or ibandronate. Osteoporos. Int. 28(6), 1995\u20132002 (2017). . https:\/\/doi.org\/10.1007\/s00198-017-3992-5","journal-title":"Osteoporos. Int."},{"issue":"5","key":"4741_CR15","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1016\/j.bone.2012.02.006","volume":"50","author":"AD Anastasilakis","year":"2012","unstructured":"A.D. Anastasilakis, S.A. Polyzos, P. Makras, G.T. Sakellariou, I. Bisbinas, A. Gkiomisi, S. Delaroudis, S. Gerou, I. Ballaouri, D. Oikonomou, S.E. Papapoulos, Acute phase response following intravenous zoledronate in postmenopausal women with low bone mass. Bone. 50(5), 1130\u20131134 (2012). . https:\/\/doi.org\/10.1016\/j.bone.2012.02.006","journal-title":"Bone"},{"key":"4741_CR16","doi-asserted-by":"publisher","first-page":"9492883","DOI":"10.1155\/2021\/9492883","volume":"2021","author":"BSA Ferreira","year":"2021","unstructured":"B.S.A. Ferreira, da B.M. Cunha, L.P. Valadares, L.A. Moreira, F.G.A. Batista, C.D.F. Hottz, M.M.P. Lins, G.G.R. Magalh\u00e3es, de L.M. Arruda, S.H.R. Ramalho, Characteristics Associated with Acute-Phase Response following First Zoledronic Acid Infusion in Brazilian Population with Osteoporosis. J. Osteoporos. 2021, 9492883 (2021). https:\/\/doi.org\/10.1155\/2021\/9492883","journal-title":"J. Osteoporos."},{"issue":"11","key":"4741_CR17","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1007\/s12325-018-0805-y","volume":"35","author":"L Blonde","year":"2018","unstructured":"L. Blonde, K. Khunti, S.B. Harris, C. Meizinger, N.S. Skolnik. Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician. Adv. Ther. 35(11), 1763\u20131774 (2018). https:\/\/doi.org\/10.1007\/s12325-018-0805-y","journal-title":"Adv. Ther."},{"issue":"1","key":"4741_CR18","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1093\/bja\/aen103","volume":"101","author":"H Breivik","year":"2008","unstructured":"H. Breivik, P.C. Borchgrevink, S.M. Allen, L.A. Rosseland, L. Romundstad, E.K. Hals, G. Kvarstein, A. Stubhaug, Assessment of pain. Br. J. Anaesth. 101(1), 17\u201324 (2008). https:\/\/doi.org\/10.1093\/bja\/aen103","journal-title":"Br. J. Anaesth."},{"issue":"4","key":"4741_CR19","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1007\/s00198-013-2576-2","volume":"25","author":"M Tadrous","year":"2014","unstructured":"M. Tadrous, L. Wong, M.M. Mamdani, D.N. Juurlink, M.D. Krahn, L.E. L\u00e9vesque, S.M. Cadarette, Comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis. Osteoporos. Int. 25(4), 1225\u20131235 (2014). https:\/\/doi.org\/10.1007\/s00198-013-2576-2","journal-title":"Osteoporos. Int."},{"issue":"1","key":"4741_CR20","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.bone.2011.01.003","volume":"49","author":"M Pazianas","year":"2011","unstructured":"M. Pazianas, B. Abrahamsen, Safety of bisphosphonates. Bone. 49(1), 103\u2013110 (2011). https:\/\/doi.org\/10.1016\/j.bone.2011.01.003","journal-title":"Bone"},{"issue":"6","key":"4741_CR21","doi-asserted-by":"publisher","first-page":"103331","DOI":"10.1016\/j.autrev.2023.103331","volume":"22","author":"F Meyer","year":"2023","unstructured":"F. Meyer, D. Wendling, C. Demougeot, C. Prati, F. Verhoeven, Cytokines and intestinal epithelial permeability: A systematic review. Autoimmun. Rev. 22(6), 103331 (2023). https:\/\/doi.org\/10.1016\/j.autrev.2023.103331","journal-title":"Autoimmun. Rev."},{"issue":"4","key":"4741_CR22","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.ophtha.2012.10.028","volume":"120","author":"DV Patel","year":"2013","unstructured":"D.V. Patel, A. Horne, M. House, I.R. Reid, C.N. McGhee, The incidence of acute anterior uveitis after intravenous zoledronate. Ophthalmology. 120(4), 773\u2013776 (2013). https:\/\/doi.org\/10.1016\/j.ophtha.2012.10.028","journal-title":"Ophthalmology"},{"issue":"1","key":"4741_CR23","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1089\/jop.2022.0094","volume":"39","author":"NA Chartrand","year":"2023","unstructured":"N.A. Chartrand, C.K. Lau, M.T. Parsons, J.J. Handlon, Y.C. Ronquillo, P.C. Hoopes, M. Moshirfar, Ocular Side Effects of Bisphosphonates: A Review of Literature. J. Ocul Pharmacol. Ther. 39(1), 3\u201316 (2023)","journal-title":"J. Ocul Pharmacol. Ther."},{"issue":"1","key":"4741_CR24","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1186\/s12891-023-06965-y","volume":"24","author":"X Zheng","year":"2023","unstructured":"X. Zheng, J. Ye, Q. Zhan, W. Zhao, Z. Liao, X. Ye, C. Qu, Prediction of musculoskeletal pain after the first intravenous zoledronic acid injection in patients with primary osteoporosis: development and evaluation of a new nomogram. BMC Musculoskelet. Disord. 24(1), 841 (2023). https:\/\/doi.org\/10.1186\/s12891-023-06965-y","journal-title":"BMC Musculoskelet. Disord"},{"issue":"6","key":"4741_CR25","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1007\/BF02556671","volume":"41","author":"S Adami","year":"1987","unstructured":"S. Adami, A.K. Bhalla, R. Dorizzi, F. Montesanti, S. Rosini, G. Salvagno, V. Lo, Cascio, The acute-phase response after bisphosphonate administration. Calcif Tissue Int. 41(6), 326\u2013331 (1987). 10.1007\/BF02556671 https:\/\/doi.org\/10.1007\/BF02556671","journal-title":"Calcif Tissue Int."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-026-04741-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-026-04741-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-026-04741-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:03:52Z","timestamp":1786367032000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-026-04741-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,10]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4741"],"URL":"https:\/\/doi.org\/10.1007\/s12020-026-04741-1","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,10]]},"assertion":[{"value":"19 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in accordance with institutional policies and approved by the IDIM Ethics Committee (Protocol number IDIM-005-2021) with waiver of written consent for anonymized data use.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declaration"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Conflict of interests","group":{"name":"EthicsHeading","label":"Declaration"}}],"article-number":"272"}}